Best AI Index Fund to Buy
Over the last two years, companies with a focus on…
Sell
22
ARKAY Quote, Financials, Valuation and Earnings
Last price:
$71.67
Seasonality move
:
-0.22%
Day range:
$70.84 - $71.77
52-week range:
$64.94 - $102.38
Dividend yield:
5.68%
P/E ratio:
17.28x
P/S ratio:
0.54x
P/B ratio:
0.68x
Volume:
21.4K
Avg. volume:
12K
1-year change:
-29.77%
Market cap:
$5.4B
Revenue:
$10.3B
EPS (TTM):
$4.15
Analysts' Opinion
-
Consensus RatingArkema SA has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $113.00, Arkema SA has an estimated upside of 57.67% from its current price of $71.67.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $113.00 representing 100% downside risk from its current price of $71.67.
Fair Value
-
According to the consensus of 1 analyst, Arkema SA has 57.67% upside to fair value with a price target of $113.00 per share.
ARKAY vs. S&P 500
-
Over the past 5 trading days, Arkema SA has underperformed the S&P 500 by -2.71% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Arkema SA does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Arkema SA revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Arkema SA reported revenues of $2.5B.
Earnings Growth
-
Arkema SA earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Arkema SA reported earnings per share of $0.35.
Enterprise value:
8.6B
EV / Invested capital:
--
Price / LTM sales:
0.54x
EV / EBIT:
19.83x
EV / Revenue:
0.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
28.17x
Price / Operating cash flow:
18.18x
Enterprise value / EBITDA:
6.72x
Gross Profit (TTM):
$2.1B
Return On Assets:
2.18%
Net Income Margin (TTM):
3.4%
Return On Equity:
4.2%
Return On Invested Capital:
2.73%
Operating Margin:
5.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $11.7B | $10.1B | $10.3B | $2.5B | $2.5B | |
| Gross Profit | -- | -- | $2.1B | $508.3M | $464M | |
| Operating Income | $1.2B | $838.9M | $755.4M | $178.1M | $130.5M | |
| EBITDA | $1.7B | $1.3B | $1.3B | $380.2M | $346.2M | |
| Diluted EPS | $10.58 | $5.07 | $4.15 | $1.08 | $0.35 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $5.1B | $5.5B | $5.8B | $5.9B | $4.8B | |
| Total Assets | $13B | $14.9B | $15.2B | $16.3B | $15.5B | |
| Current Liabilities | $2.1B | $2.9B | $2.6B | $3.1B | $2B | |
| Total Liabilities | $6.6B | $7.3B | $7.2B | $7.7B | $7.3B | |
| Total Equity | $6.4B | $7.6B | $8B | $8.6B | $8.2B | |
| Total Debt | $3.3B | $3.6B | $3.9B | $4.6B | $4.2B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.6B | $1.3B | $1.1B | $92.3M | $23.1M | |
| Cash From Investing | -$766.8M | -$1.5B | -$1B | -$204.2M | -$191.5M | |
| Cash From Financing | $7.8M | $609.3M | -$1.4B | $399.7M | -$798.6M | |
| Free Cash Flow | $796.9M | $607.7M | $305.2M | -$92.3M | -$176.8M | |
ARKAY
Sector
Market Cap
$5.4B
$18.3M
Price % of 52-Week High
70%
64.4%
Dividend Yield
5.68%
0%
Shareholder Yield
5.76%
0.87%
1-Year Price Total Return
-29.77%
-17.17%
Beta (5-Year)
1.113
0.773
Dividend yield:
5.68%
Annualized payout:
$3.79
Payout ratio:
80.65%
Growth streak:
4 years
Technicals
8-day SMA
Sell
Level
$72.70
200-day SMA
Sell
Level
$82.14
Bollinger Bands (100)
Sell
Level
72.1 - 84.22
Chaikin Money Flow
Buy
Level
303.6K
20-day SMA
Sell
Level
$74.57
Relative Strength Index (RSI14)
Sell
Level
41.87
ADX Line
Sell
Level
15.83
Williams %R
Neutral
Level
-75.9641
50-day SMA
Sell
Level
$74.34
MACD (12, 26)
Sell
Level
-0.86
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
106.7K
Financial Scores
Hold
Altman Z-Score
(Annual)
Level (1.8423)
Buy
CA Score
(Annual)
Level (-0.067)
Buy
Beneish M-Score
(Annual)
Level (-2.7597)
Sell
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.0098)
Buy
Piotroski F Score
(Annual)
Level (4)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Arkema SA is a French chemical company formerly known for its large presence in the acrylics market. However, the company has now developed a strong portfolio of speciality materials. Arkema is organized into four segments. Adhesive solutions, advanced materials, and coatings solutions contain the more specialized material businesses. The intermediates segment houses the remaining commodity chemical businesses. Geographically, sales are split fairly equally among Europe, the US, and Asia.
Stock Forecast FAQ
In the current month, ARKAY has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ARKAY average analyst price target in the past 3 months is $113.00.
-
Where Will Arkema SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that Arkema SA share price will rise to $113.00 per share over the next 12 months.
-
What Do Analysts Say About Arkema SA?
Analysts are divided on their view about Arkema SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Arkema SA is a Sell and believe this share price will drop from its current level to $113.00.
-
What Is Arkema SA's Price Target?
The price target for Arkema SA over the next 1-year time period is forecast to be $113.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ARKAY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Arkema SA is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of ARKAY?
You can purchase shares of Arkema SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Arkema SA shares.
-
What Is The Arkema SA Share Price Today?
Arkema SA was last trading at $71.67 per share. This represents the most recent stock quote for Arkema SA. Yesterday, Arkema SA closed at $71.67 per share.
-
How To Buy Arkema SA Stock Online?
In order to purchase Arkema SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Salesforce Stock Be in 5 Years?
Salesforce (NYSE: CRM) just turned in a quarter that, on…
2 Ultra Safe Dividend Stocks to Buy Now
Historically, blue-chip dividend stocks have been good choices for periods…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
65
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
31
REGN alert for May 31
Regeneron Pharmaceuticals [REGN] is down 19.04% over the past day.
Buy
55
RGC alert for May 31
Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.
Sell
42
AMBA alert for May 31
Ambarella [AMBA] is down 15.13% over the past day.
